DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex
Metrics: PDF 1350 views | HTML 594 views | ?
Wataru Nakajima1,2,*, Kanika Sharma1,*, June Young Lee1, Nicolas T. Maxim1, Mark A. Hicks1, Thien-Trang Vu1, Angela Luu1, W. Andrew Yeudall3, Nobuyuki Tanaka2, Hisashi Harada1
1Phillips Institute for Oral Health Research, School of Dentistry, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
2Department of Molecular Oncology, Institute for Advanced Medical Sciences, Nippon Medical School, Kawasaki, Japan
3Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, Georgia, USA
*These authors contributed equally to this work
Hisashi Harada, email: email@example.com
Keywords: CDK2, MCL-1, Noxa, phosphorylation, chemotherapy
Received: September 08, 2015 Accepted: April 24, 2016 Published: May 07, 2016
Noxa, a BH3-only pro-apoptotic BCL-2 family protein, causes apoptosis by specifically interacting with the anti-apoptotic protein MCL-1 to induce its proteasome-mediated degradation. We show here that the DNA damaging agents cisplatin and etoposide upregulate Noxa expression, which is required for the phosphorylation of MCL-1 at Ser64/Thr70 sites, proteasome-dependent degradation, and apoptosis. Noxa-induced MCL-1 phosphorylation at these sites occurs at the mitochondria and is primarily regulated by CDK2. MCL-1 and CDK2 form a stable complex and Noxa binds to this complex to facilitate the phosphorylation of MCL-1. When Ser64 and Thr70 of MCL-1 are substituted with alanine, the mutated MCL-1 is neither phosphorylated nor ubiquitinated, and becomes more stable than the wild-type protein. As a consequence, this mutant can inhibit apoptosis induced by Noxa overexpression or cisplatin treatment. These results indicate that Noxa-mediated MCL-1 phosphorylation followed by MCL-1 degradation is critical for apoptosis induced by DNA damaging agents through regulation of the Noxa/MCL-1/CDK2 complex.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.